Forte Biosciences Inc FBRX

Healthcare Biotechnology

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

NDAQ:FBRX - Post by User

Forte Biosciences Inc

<< Previous

Bullboard Posts

Post by IronFocus77on Dec 04, 2024 9:28am

26 Views

Post# 36344857

$FBRX Advances, $MYNZ Steadies

$FBRX adds 2.3%, hitting $24.00 as market enthusiasm for its dermatological treatments grows. In the same biotech sphere, $MYNZ stabilizes after its reverse split, emphasizing its focus on innovative cancer detection technology.

<< Previous

Bullboard Posts

Bitcoin Well increases reserve amid strong subscriber growth